Sanofi: 2026Q2 Earnings

Latest Quarterly Earnings Summary (Q2 2026)

Financial Highlights

• Net Sales: Reached €11.60 billion, representing a 17.8% increase year-over-year at constant exchange rates (CER).
• Business EPS: Climbed 33.3% CER to €2.09.
• Business Operating Income (BOI): Surged 35.8% CER to €3.29 billion, expanding the operating margin to 28.4%.
• H1 Free Cash Flow: Rose 51.5% year-over-year to €3.72 billion.

Portfolio & Growth Drivers

• Dupixent Milestone: Quarterly sales surpassed €5 billion for the first time in company history, reaching €5.15 billion (+37.6% CER) driven by sustained global volume expansion.
• Pharma Launch Portfolio: Accelerated 48.3% CER to €1.31 billion, led by key launches such as ALTUVIIIO, Ayvakit, and Sarclisa.
• Vaccines Division: Sales reached €1.15 billion, declining 4.7% CER due to high baseline comparisons from prior-year flu vaccine demand.

R&D & Pipeline Prioritization

• R&D Expenditure: Rose 17.9% to €2.23 billion as part of strategic R&D alignment and pipeline restructuring.
• Impairment Impact: Recorded ~€1.03 billion in intangible asset impairment charges (primarily related to amlitelimab prioritization and asset write-downs), impacting reported IFRS net profit.

Upgraded Full-Year 2026 Guidance

• Sales Growth: Elevated full-year 2026 net sales target from high single digits to around 10% at CER.
• Earnings Outlook: Full-year Business EPS is projected to grow slightly faster than net sales.

According to Sanofi’s latest official Q2 2026 financial report, total net sales reached €11.597 billion. Sanofi’s business is primarily divided into two core segments: Biopharmaceuticals and Vaccines. Biopharmaceuticals is further broken down into Specialty Care and General Medicines, while Consumer Healthcare (Opella) has been accounted for as discontinued operations/carve-out.

Below is the revenue breakdown and a brief description of each segment/product category:

1. Specialty Care

• Revenue Share: Approximately 68% to 70% (approx. €7.98 billion)
• Description: Sanofi’s core and fastest-growing revenue engine. It encompasses Immunology, Rare Diseases, Rare Blood Disorders, Oncology, and Neurology. The flagship product Dupixent generated quarterly sales of €5.154 billion, representing about 44.4% of total revenue alone. The Pharma Launches portfolio (including ALTUVIIIO, Ayvakit, Sarclisa, etc.) contributed roughly 11.2% (€1.305 billion).

2. General Medicines

• Revenue Share: Approximately 20% to 22% (approx. €2.46 billion)
• Description: Includes legacy cardiovascular diseases, diabetes (such as the long-acting insulin Lantus), and various mature patented prescription drugs. As Sanofi has discontinued early-stage R&D in this field, this segment primarily serves as a stable base cash generator to support company transformation and high-end R&D expenditures.

3. Vaccines

• Revenue Share: Approximately 9.9% (€1.15 billion)
• Description: Includes influenza vaccines, polio/pertussis/Hib (PPH) vaccines, meningitis vaccines, and the novel RSV preventive monoclonal antibody Beyfortus. The vaccine business features high barriers to entry and government procurement stickiness, showing strong seasonal quarterly patterns (typically peaking in influenza and RSV immunization seasons during Q3 and Q4).

4. Consumer Healthcare (Opella)

• Revenue Share: Classified as discontinued operations/spin-off disposal
• Description: Includes OTC non-prescription drugs and personal care products such as allergy medications, analgesics, and digestive health products. Sanofi has initiated its spin-off and capital independence plan to transform the group into a 100% pure-play biopharmaceutical enterprise.

Source: Sanofi Q2 2026 Earnings Release

Key Quarterly Developments (Q2 2026)

• Strong Double-Digit Top- and Bottom-Line Growth: Net sales reached €11.60 billion (+17.8% CER), with Business EPS up 33.3% CER to €2.09, prompting management to upgrade full-year 2026 sales growth guidance to ~10%.
• Dupixent Milestone: Dupixent quarterly sales surpassed €5 billion for the first time in history, hitting €5.15 billion (+37.6% CER), driven by continuous volume expansion and reaching over 1.5 million patients globally.
• Pharma Launch Acceleration: High-growth pharma launches surged 48.3% CER to €1.31 billion, spearheaded by momentum across ALTUVIIIO, Ayvakit, and Sarclisa.
• Pipeline Prioritization & Impairment Charges: Discontinued clinical development of amlitelimab in atopic dermatitis (AD) alongside the termination of itepekimab and balinatunfib programs. This pipeline restructuring incurred ~€1.03 billion in non-recurring impairment charges, impacting reported IFRS net profit.
• Capital Allocation Execution: Completed the previously announced €1 billion share buyback program during the quarter.

Key Priorities & Catalysts for Next Quarter (Q3 2026)

• Vaccines Seasonality & RSV Pull-Through: Management anticipates a temporary, low- to mid-teens year-over-year decline in Q3 vaccine sales due to tough prior-year flu comparison baselines. The primary focus will be tracking commercial adoption and inventory stocking of Beyfortus (RSV mAb) for the upcoming Northern Hemisphere immunization season.
• H2 Growth Normalization: As baseline comparisons step up and R&D cost reimbursements from Regeneron wind down, Dupixent revenue growth is expected to normalize at lower double-digit rates. Investors will monitor market penetration in new indications like chronic obstructive pulmonary disease (COPD).
• Margin & Tax Dynamics: Evaluation of whether royalty income streams (e.g., Amvuttra) can fully offset reduced R&D funding contributions from partners, alongside navigating an anticipated ~21% full-year effective tax rate.

Long-Term Future Outlook

• Upgraded FY 2026 Guidance: Full-year 2026 net sales growth is projected at around 10% at CER, with Business EPS expected to grow slightly faster than net sales.
• Elevated 2030 Targets: Management raised its 2030 peak sales ambition for Dupixent to ~€25 billion and expects the new Pharma Launch portfolio to generate ~€10 billion annually by 2030.
• Pure-Play BioPharma Completion: The carve-out of Consumer Healthcare (Opella) remains on track, solidifying Sanofi’s 100% strategic pivot toward high-margin, innovative biopharmaceuticals.
• AI Integration & R&D Execution: Accelerating pipeline output through its plai decision engine, CodonBERT foundation models, and alliances with OpenAI and Formation Bio to rebuild late-stage pipeline velocity following recent program discontinuations.

Back to Sanofi